Skip to main content
VRCA logo

VRCA · Verrica Pharmaceuticals Inc.

Track VRCA — free
$3.56 -0.16 (-4.30%) At close · Nov 13
Market Cap
$61.16M
Shares
17.18M
Volume · Nov 13 18.68K Avg daily vol (3M) 72.22K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.56 Open$3.75 Day$3.40–3.92 52W close$3.09–9.10 Avg vol 30d58K Short int244K · 1.4% of shares · 4.6d Short vol48% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 13

Up next

Mar 10, 2027 Est · unconfirmed · in 16 wks

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash of $14.4 million raises substantial going-concern doubt

Verrica Pharmaceuticals reported $14.4 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern within one year. Nine-month YCANTH product revenue rose to $15.1 million from $11.6 million.

Revenue $6.91M ▼ 51.8% Net loss $12.41M Diluted EPS -$0.58
Read from the MD&A section
3 source passages
As of September 30, 2026, we had cash of $14.4 million. Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Product revenue, net was $15.1 million for the nine months ended September 30, 2026, compared to $11.6 million for the nine months ended September 30, 2025. Open the document at this passage
Nov 12
Earnings call
Wycanth revenue reached $5.7 million as trials advanced

Verrica Pharmaceuticals reported U.S. Wycanth product revenue of $5.7 million in the third quarter of 2026. One Phase III trial completed enrollment, the second exceeded 50% enrollment, and readouts are expected in the first quarter of 2027 and mid-2027.

5 source passages
U.S. net Wycanth product revenue was $5.7 million in the third quarter of 2026. In August, we announced the completion of enrollment in COVID-2, the first pivotal Phase III trial, after an interim analysis confirmed that no additional patients were recommended for enrollment. And in late August, we announced that enrollment has exceeded 50% of its current target. We expect top-line data from COVID-2 to be available in the first quarter of 2027. We expect top-line data from this trial to be available by mid-2027. Open the document at this passage
Nov 12
Current report 8-K
Record YCANTH revenue reaches $5.7 million as COVE-2 enrollment completes

Verrica Pharmaceuticals Inc. reported record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 57.9% year-over-year. COVE-2 enrollment is complete, with topline data expected in Q1 2027; COVE-3 enrollment exceeds 50%, with topline data expected in mid-2027.

Financial results
2 source passages
During the third quarter, the Company recorded YCANTH net product revenue of $5.7 million, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million. On August 27, 2026, the Company announced completion of enrollment in the first pivotal Phase 3 trial (COVE-2) studying YCANTH for the treatment of common warts and greater than 50% enrollment in the second pivotal Phase 3 trial (COVE-3). Topline data readouts for the trials are expected in the first quarter of 2027 and mid-2027, respectively. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $5.86M ▼ 53.8% Net loss $13.15M Diluted EPS -$0.62
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$22.89M
Trailing 12 months
Net income (TTM)
−$43.32M
Trailing 12 months
Revenue growth YoY
-51.8%
Year over year
Operating margin
-184.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$30.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+124.5%
Year over year · more shares
Price change (1Y)
-8.0%
Trailing year
Short interest
1.4%
Latest settlement · 4.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. YCANTH net product revenue grew 11.9% sequentially and 57.9% year over year with improved gross-to-net yield, while both pivotal common-warts trials advanced toward 2027 readouts. The remaining $15.0 million under the $27.5 million credit facility was unlocked, extending cash runway into the fourth quarter of 2027, but total revenue declined, losses widened, and research and development and selling, general and administrative expenses increased.

Bullish
  • + YCANTH net product revenue reached $5.7 million, up 11.9% sequentially and 57.9% year over year.
  • + Enrollment was completed in COVE-2, COVE-3 was more than 50% enrolled, and topline data are expected in the first quarter of 2027 and mid-2027, respectively.
  • + The $27.5 million credit facility's remaining $15.0 million was unlocked, extending cash runway into the fourth quarter of 2027.
  • + YCANTH product growth was supported by improved gross-to-net yield from reduced co-pay assistance spending.
  • + Pooled registrational-trial analyses indicated that YCANTH-treated patients achieved complete clearance approximately four times faster than placebo and at each visit, three times as many treated patients achieved clearance.
  • + Verrica is exploring VP-315 development for Gorlin syndrome, an indication with no current FDA-approved products.
Bearish
  • − Total revenue declined to $6.9 million from $14.3 million because the prior-year period included a $10.0 million one-time Torii milestone payment.
  • − GAAP net loss widened to $12.4 million, or $0.58 per share, from a $0.3 million loss, or $0.03 per share.
  • − Non-GAAP results moved from $1.1 million of income in 2025 to a $10.5 million loss in 2026.
  • − Research and development expense rose to $7.6 million from $2.2 million.
  • − Selling, general and administrative expenses increased to $10.4 million from $9.4 million.
  • − Interest income declined to $45,000 from $0.2 million, primarily because cash balances were lower.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −34%
below
Price vs 50-day avg −12%
below
RSI (14) 47
neutral
MACD trend Positive
52-week position 8%
near low
Momentum
relative strength
Very Weak
1-month return −1%
trailing
6-month return −41%
trailing
YTD return −57%
this year
Relative strength −41%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
30 of 43 funds reported for Sep 30 · net +19.8K sh shares · +2 new
Insider flow Accumulating
Net +$34.6K over 90 days · 0% sells
Short interest Rising
1.42% of shares out · ▲ +26.9% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
43 holders — mid 3-yr range
Squeeze score 60
elevated · 0–100
Fundamentals
Strong
Revenue growth +370%
Y/Y
EPS growth +89%
Y/Y
Free cash flow $-17.6M
Balance sheet $30.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −66%
past year
ATR 9.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 12, 2026
First $40 million of payments for this program · future periods $40M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−34% Bearish
Price vs 50-day avg
−12% Bearish
RSI (14)
47 Neutral
MACD trend
Positive Bullish
52-week position
8% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
30 of 43 funds reported for Sep 30 · net +19.8K sh shares · +2 new
Insider flow Accumulating
Net +$34.6K over 90 days · 0% sells
Short interest Rising
1.42% of shares out · ▲ +26.9% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
43 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $4 · 8% Range high $9
vs 200-day avg -34% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Company's share 3.7M three months ended September 30, 2026 filing —
contra-research and development expense 0.3M three months ended September 30, 2026 filing —
total program costs incurred under the arrangement 7.4M three months ended September 30, 2026 filing —
Non-GAAP net loss non-GAAP $19M six months ended June 30, 2026 —
Non-GAAP net loss per share non-GAAP $0.89 six months ended June 30, 2026 —
YCANTH dispensed applicator units 19,626 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VRCA
Verrica Pharmaceuticals Inc.
this stock
$61.16M -57.2% +370.2% — 1.4%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
41
% held
27.3%
Reported
30 of 43
Top holder
Caligan Partners LP
Held Float
View
Held by Funds
Fund positions
18
View
Short & Settlement
Short Interest Rising
Shares short
244.4K
Days to cover
4.6d
Change
+51.8K sh
View
Short Volume
Short vol %
48%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
4
Value
$18
As of
Sep 21, 2026
View
Off-Exchange
Off-exchange %
48.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$34.6K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$35.6M
Net income (FY)
$-17.9M
EPS diluted
$-1.68
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 13, 2026
This year
12

Verrica Pharmaceuticals reported $14.4 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern within one year. Nine-month YCANTH product revenue rose to $15.1 million from $11.6 million.

View
Proposed Sales
Value
$94.3K
Shares
36.0K
Filed
Aug 26, 2024
View
Exempt Offerings
Offering
$50.0M
Filed
Dec 10, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 19, 2026
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Verrica Pharmaceuticals Reports T…
Published
Nov 12, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
VRCA +11.6% -1.0% -40.9% +6.3% -57.2%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +9.0% +0.2% -41.4% +6.5% -67.8%
Key facts CIK 1660334 CUSIP 92511W207 13F (30d) 46 filings 25 filers Visit website Investor relations